Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Petróleo Brasileiro SA (PBR) Price & Performance

DexCom, Inc.Trade
Petróleo Brasileiro SATrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Petróleo Brasileiro SA — how do they compare? DexCom, Inc. trades at $89.27 (market cap $33.79B), while Petróleo Brasileiro SA trades at $17.88 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 3.3× DexCom, Inc.'s market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.

DXCMPBR
Market Cap
$33.79B$112.19B
Sector
HealthTechnology
52-Week High
$89.53$22.03
52-Week Low
$54.84$11.54
Enterprise Value
$33.24B$172.61B
Dividend Yield
9.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.

The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.

Petróleo Brasileiro SA

Petrobras (PBR) trades at $17.93, down 2.18% today, showing strong fundamentals with a P/E of 4.53 and robust profitability margins. Recent Q2 2026 earnings beat expectations with EPS of $1.60 versus $1.40 expected, driven by record production and higher oil prices. Technical indicators signal bearish momentum, with RSI at oversold levels near 20.31, while analyst consensus remains positive with 50% buy ratings.

The outlook remains favorable due to cheap valuations and production growth, but risks include regulatory uncertainty and volatile oil prices. Investment opportunity lies in sustained dividend payments and operational efficiency, though geopolitical and macroeconomic factors could pressure near-term performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Petróleo Brasileiro SA

Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.

Read more on PBR